Pharmacotherapy for Colorectal Cancer
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (30 November 2022) | Viewed by 2028
Special Issue Editor
Interests: colon cancer; apoptosis; medicinal plants; anticancer compounds; multitarget drugs; multidrug resistance; polyphenols; synergistic properties of therapeutic agents
Special Issue Information
Dear Colleagues,
Colorectal carcinoma is one of the most frequent malignant cancers of the gastrointestinal tract. Each year, 1.8 million new cases of this cancer are identified worldwide, and the global mortality amounts to 862,000 deaths. Despite the impressive development of medicine, so far, it has not been possible to find a fully effective method for treating this and other cancers. Numerous studies have shown that among the patients who have been treated only surgically, there is the highest risk of recurrence and metastatic changes. Therefore, the methods of surgical treatment are usually part of combination therapy that additionally includes radiotherapy and chemotherapy. Unfortunately, in the process of defending the malignant cells against the activity of cytotoxic drugs used in chemotherapy, many signal pathways are involved, which leads to the insufficient effectiveness of the pharmacological treatment. New compounds that could manifest potential anticancer activity are therefore constantly studied. Because of the multifactorial character of cancers, searching for an effective therapeutic substance is oriented towards the so-called multifunctional drugs, which at the same time affect several biological targets.
As a guest editor, I invite you to contribute your latest research findings or updated reviews to this Special Issue focused on pharmacotherapy for colorectal cancer and the implementation of combination therapies that entail the combined use of two or more cancer-cell-growth inhibitors. The simultaneous use of many active substances can increase the risk of side-effects, but the skillful use of the interactions that occur among them allows increasing their effectiveness and the safety of the therapy.
Dr. Kamila Środa-Pomianek
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- colon cancer
- apoptosis
- medicinal plants
- anticancer compounds
- multitarget drugs
- cytotoxicity
- polyphenols
- synergistic properties of therapeutic agents
